Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition

The development of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors is the most significant breakthrough in the lipid-lowering field since the advent of statins. This class of drugs has the ability to lower low-density lipoprotein cholesterol (LDL-C) an additional 60%, even in patients on high-intensity statins, resulting in achieved LDL-C levels that are often <40 mg/dL. These very low levels of achieved LDL-C not only are safe but also have a profound impact on cardiovascular health. With incorporation into the guidelines and a push toward lower LDL-C goals, PCSK9 inhibitors have an important and expanding role in the treatment and prevention of cardiovascular disease.